Technical Analysis for SHPG - Shire plc
|Grade||Last Price||% Change||Price Change|
SHPG closed up 1.19 percent on Thursday, April 27, 2017, on 66 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.
Earnings due: May 2
Trend Table & Recent Alerts
|Weak or Absent||Down||Up||Up|
|See historical SHPG trend table...|
|Date||Alert Name||Type||% Chg|
|Apr 27||Crossed Above 50 DMA||Bullish||0.00%|
|Apr 27||Stochastic Reached Overbought||Other||0.00%|
|Apr 26||Fell Below 50 DMA||Bearish||1.19%|
|Apr 25||Crossed Above 50 DMA||Bullish||0.66%|
|Apr 24||Non-ADX 1,2,3,4 Bearish||Bearish Swing Setup||1.21%|
|Apr 21||NR7||Range Contraction||3.43%|
|Apr 21||Non-ADX 1,2,3,4 Bearish||Bearish Swing Setup||3.43%|
|Apr 19||Stochastic Reached Oversold||Other||5.06%|
|Apr 17||Non-ADX 1,2,3,4 Bearish||Bearish Swing Setup||3.50%|
|Apr 13||Shooting Star Candlestick||Bearish||3.91%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Shire plc, a specialty biopharmaceutical company, engages in the research and development, manufacture, sale, and distribution of pharmaceutical products. It operates in three segments: Specialty Pharmaceuticals (SP), Human Genetic Therapies (HGT), and Regenerative Medicine (RM). The SP segment offers products for the treatment of attention deficit and hyperactivity disorder (ADHD), including VYVANSE/VENVANSE, a pro-drug stimulant; INTUNIV, an alpha-2A receptor agonist; EQUASYM, a methylphenidate hydrochloride; and ADDERALL XR, an extended release treatment for ADHD. It also produces PENTASA and LIALDA/MEZAVANT for the treatment of ulcerative colitis; and RESOLOR, a 5-HT4 receptor agonist for oral symptomatic treatment of chronic constipation in women. In addition, this segment provides FOSRENOL, a phosphate binder for use in end-stage renal failure patients receiving dialysis; and XAGRID for the reduction of elevated platelet counts in at-risk essential thrombocythemia patients, as well as for the treatment of thrombocythemia. The HGT segment offers REPLAGAL for the treatment of Fabry disease; ELAPRASE for the treatment of hunter syndrome; VPRIV for the treatment of type 1 Gaucher disease; and FIRAZYR for the symptomatic treatment of acute attacks of hereditary angioedema. The RM segment provides DERMAGRAFT, a bio-engineered skin substitute that assists in restoring damaged tissue. The company also licenses its patented antiviral products for human immunodeficiency virus and hepatitis B virus. In addition, it is developing various products in the areas of behavioral health, gastrointestinal, HGT, RM, and other therapeutic areas. The company markets its products directly to government hospitals, clinics, pharmacies, and other agencies; and through wholesalers and distributors. It has operations in North America, the United Kingdom, the Republic of Ireland, and internationally. Shire plc was founded in 1986 and is headquartered in Dublin, Ireland.
Is SHPG a Buy, Sell or Hold?
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more SHPG news...
|52 Week High||209.22|
|52 Week Low||161.09|
|200-Day Moving Average||181.3465|
|50-Day Moving Average||176.7988|
|20-Day Moving Average||173.0115|
|10-Day Moving Average||173.165|
|Average True Range||2.6807|
|Chandelier Exit (Long, 3 ATRs)||170.5579|
|Chandelier Exit (Short, 3 ATRs)||176.3021|
|Upper Bollinger Band||178.9546|
|Lower Bollinger Band||167.0684|
|Percent B (%b)||0.91|